Key Highlights

  • Biodexa shares are trading 5.09% higher at $4.13 on Wednesday, October 28, 2026, up from an implied prior close of about $3.93 (calculated).
  • The company enrolled its 100th patient in the Phase 3 Serenta trial of eRapa on October 13, 2026, out of 168 planned.
  • A futility analysis after 25 progression events could occur early next year, per the October 13 release.
  • Each ADS moved from 50 to 400 ordinary shares on or about October 26, 2026, an eightfold increase.
  • Cash and equivalents stood at 8.534 million pounds at December 31, 2025, with no long-term debt.

Biodexa Stock Move: Why Is the Penny Stock Up 5% After a Reverse ADS Split?

Biodexa Pharmaceuticals (NASDAQ:BDRX) shares are trading 5.09% higher at $4.13 on Wednesday, October 28, 2026. The implied prior close is about $3.93 (calculated from the price and percentage change). The stock is on the most shorted list, and trading in the ADSs was halted pending news in late October.

No new dated release accompanied today's move. The recent events are the October 13 trial update and the ratio change announced on October 8, which converted eight old ADSs into one new ADS from on or about October 26, 2026.

Short Interest in Biodexa: What Could It Mean for a Float This Small?

The latest short-interest data shows 18,380 shares sold short, or about 0.83% of shares outstanding, against 271,866 a month earlier. The reported float is 943,491 shares and the market capitalisation was about $3.80 million at the October 26 close of $3.69.

With so few tradable ADSs, a small number of shares can move the price in either direction. High short interest in a thin float can add to volatility if short sellers buy to cover, but it can also reflect doubts about funding or dilution.

Serenta Trial: Is eRapa Nearing a Futility Analysis in Familial Adenomatous Polyposis?

Biodexa is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on familial adenomatous polyposis (FAP), gastrointestinal stromal tumours, bladder cancer and type 1 diabetes. Its main asset, eRapa, is a rapamycin formulation that received FDA fast track designation on February 10, 2025.

On October 13, 2026, the company said it had enrolled 100 patients in the registrational Serenta trial, which plans 168 patients randomised 2:1 against placebo at 29 sites in the United States and five European countries. A futility analysis after 25 progression events could occur early next year, per management, with database lock after 75 events possibly around the end of next year. A 20 million dollar state cancer research grant supports the program.

Biodexa Pipeline and Funding: How Long Does the Cash Last?

In February 2026 Biodexa licensed MTX240, a molecular glue for gastrointestinal stromal tumours, from Otsuka, with plans to secure a manufacturer, file an investigational application and start a Phase 1b/2a study.

Cash and equivalents were 8.534 million pounds at December 31, 2025, with total equity of 11.539 million pounds and no long-term debt. A December 2025 offering raised about $10.0 million in gross proceeds, and a warrant exercise brought in $2.3 million on September 15, 2026.

What to Watch Next: Futility Analysis Timing and the Next Financing

Investors will follow progress toward the 25-event futility analysis, enrollment of the remaining 68 patients, MTX240 manufacturing and filing steps, and any new capital raise.